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The existence of immunity to cancer was postu
lated by the eminent scientists who helped to estab
lish the discipline of immunology. In 1907 Clowes
suggested that human resistance to cancer resulted
from what we. today call "immune surveillance." 1•
During the ensuing 70 years the results obtained from
experimental animal cancers and human cancers have
greatly influenced the palatability of tumor-immunity
theories.3·' Early optimism that immunity to cancer
could be specifically induced waned and almost dis
appeared when it was demonstrated that the rejection
of cancer transplants resulted from transplantation
immunity and not tumor immunity. A sustained
wave of enthusiasm for immunity to cancer appeared
after demonstrations that inbred animals could be
immunized to cancers arising in the inbred strain.5·
The objective of this paper is to try to reexamine
many aspects of cancer immunology and to shift the
emphasis currently placed on some of these aspects
into other areas with greater potential for clinical
application. This is not meant to be one of the numer
ous reviews of cancer immunology but rather a bal
anced presentation of alternative viewpoints which
will ultimately tilt toward my viewpoint.
The plan for the paper is as follows: ( I ) the types
of contributions immunology has made to mankind
will be briefly reviewed: (2) a general theory describ
ing cancer immunity with some supporting evidence
will be presented not once but twice: (3) finally the
current status of immunotherapy of human cancer
will be briefly mentioned.
Co111ribwions o/Im111uno/ogy.
A review of the major contributions of immu
nology to humanity should offer a preview of what
can reasonably be expected from future contributions
2
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of this field to the understanding and control of can
cer. The trademark of immunology is prevention of
disease by immunization. With the discovery of anti
biotics and their use in tissue cultures. a fresh attack
upon many viral infections became possible. In the
past two decades. the cultivation of viruses in vitro
has resulted in the elimination of epidemics of po
liomyelitis: infection with measles virus is less com
mon. Where the human is the sole host and reservoir
of an infection. immunization may lead to the eradi
cation of a disease. This appears to be the attainable
goal in smallpox where we are at the threshold of its
eradication by intensive immunization and epidemio
logic field work.
While the trademark is immunization. the work
horse of immunology is serology. lls use in diagnosis
and blood banking alone are of critical importance to
the functioning of our hospit<c1ls. A strike of all tech
nicians doing serologic tests would paralyze our
health care system. In addition to its diagnostic con
tributions. immunology provides an important un
derstanding of the pathogenesis of disease.
A relatively new but potentially major contribu
tion is in predicting susceptibility to disease. The
association of certain transplantation antigens with
specific disease states may be the forerunner of sero
logic identification of disease-risk factors.
When one turns to the role of immunology in
therapy. the work seems harder and the results hardly
optimal. This view is not meant to belittle the value of
replacement therapy in certain immune deficiency
diseases, or of immunosuppressive therapy in pre
venting transplant rejection: rather it is intended to
point out that cancer immunology is much, much
more than immunotherapy.
Grneral Frn1ures of" /111111uni1y 10 Cancer.
All cancer immunology is inextricably linked to
the existence of an antigenic difference between the
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cancer cell and its closest normal "relative'' cells.
Without such a difference, immunology has no entry
into the cancer field.
The transformation of a normal cell to a cancer
cell is probably accompanied by an antigenic change.
This transformation may occur frequently in all of us.
With a properly functioning immune system, the an
tigenic change or changes in the cancer cells are rec
ognized and following recognition an effective anti
cancer cell immune response destroys the malignant
cells. Appearance of clinical cancer is thus considered
to be a prima facie case of a failure of normally
operating immunologic mechanisms.
Ei;idence Supporting Immune Surveillance.

Origins for cancer antigens are not hard to find.
Oncogenic viruses are obvious sources of extraneous
antigenic material incorporated into cancer cells.
While no human oncogenic virus has been clearly
identified, several viruses are viewed with suspicion.
Chemical compounds play an important role in the
initiation of human cancer, and for many years these
carcinogens included many compounds that are also
mutagens. Recently a bacterial test for detecting
chemical mutagens has shown that almost every
known chemical carcinogen is either a mutagenic
agent or is metabolized to a mutagen.' Chemical
carcinogen-induced changes in the bases of deoxyri
bonucleic acid (DNA) can result in the synthesis of
abnormal. that is, antigenic, proteins. Similarly.
physical agents such as ultraviolet and x-irradiation
are also known carcinogens and mutagens.
Amongst the wide variety of human cancers, an
impressive list of cancer-associated "time and place"
antigens have been detected.•- 1 0 The carcinoembry
onic antigen of the gastrointestinal tract. alpha-feto
protein. chorionic gonadotropin, antidiuretic hor
mone. and parathormone are examples of normal
product made by cancers that are either abnormal
for postnatal life or for that type of cell.
As we move to consider the evidence for the
existence of immune cancer-rejection systems, we
need to rely on negative observations. It is impossible
to demonstrate that we are cancer-free as a result of
active recognition and destruction of small clones of
cancer cells. but strong circumstantial evidence
points to such immune mechanisms. Patients who are
recipients of organ transplants have a high risk of
subsequently developing a malignant disease 11 ·12 :
these patients are estimated to be at least 25 times
more likely to develop cancer than the normal popu
lation.

An additional group of patients at high risk for
developing cancer are those individuals with im
munodeficiency diseases. From 5% to I 0% of patients
with sex-linked agammaglobulinemia, combined im
munodeficiency disease, Wiskott-Aldrich, or ataxia
telangiectasia will develop clinical malignant disease.
Further but less definite indications that we are pro
tected by immune mechanisms include the observa
tions that chemical carcinogens may be immunosup
pressive,1• the claims of cutaneous anergy in patients
with neoplastic disease, 1'- 1' and the frequently stated
view that patients with cancer have an increased sus
ceptibility to infection. 1 •
The last element to be considered in the con
struction of an immunologic lattice for the contain
ment of cancer is the alteration of the course of
cancer by immunologic methods-immunotherapy.
Attempts to stimulate a specific immune response 1'
and to stimulate the entire immune response by
agents like bacille Calmette Guerin (BCG )'0 have
been extensively performed. In 1971, a comprehen
sive review was published by Yashpie,'1 and the re
port of a conference entitled. "lmmunotherapy of
Cancer: Present Status of Trials in Man," held in
Washington in October, 1976, is to be published.
How effective is immunotherapy for human can
cer? It is important to realize that the concept of the
"proof of the pudding is in the eating" is as much
determined by how hungry one is as by the quality of
the pudding. Rather than enthuse about immuno
therapy, I prefer to accept its present meagre results
as a challenge to reexamine our entire position. I will
also consider immunology with respect to prevention,
pathogenesis, early diagnosis, treatment monitoring
aids, and immunotherapy.
Prevention of Human Cancer by Vaccines.

An extensive review of the possibilities in this
area was recently published." At least two major
obstacles need to be overcome before vaccines for
human cancer become a reality. First and foremost
the link between a human virus and the cancer it
causes needs to be firmly established. Then the virus
can be developed into a vaccine-living, killed. or
subunit. The second problem is to determine who
should receive the vaccine. Since the incidence of any
one kind of carcinoma is relatively low, methods are
needed to identify the high-risk groups. Where the
prevalence of a carcinoma may be 5 to 10 persons per
100,000, it would be unacceptable to try to immunize
the whole population.
Where a viral-associated neoplasm behaves like
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a communicable infectious disease, a vaccine could
be very helpful. Such a situation exists in the poultry
industry. A DNA herpes-like virus (Marek's disease
virus) is manufactured into a fully infectious form in
the feather follicle of the chicken. In addition this
virus spreads within the chicken and causes a fatal
lymphoreticular disease; it also spreads amongst
chickens and can wipe out a flock. An effective vac
cine has been prepared from an apparently harmless
herpes virus of turkeys. This vaccine protects the
chickens against Marek's disease!•
The Pathogenesis of Cancer.
Immunologists searching for human cancer anti
gens have made an astounding, although largely ig
nored, contribution to our understanding of the
pathogenesis of cancer. Despite years of search by
numerous competent investigators, a cancer-specific
antigen has not been isolated for any human cancer.
Although the search for cancer-specific antigens is
too important to be abandoned, the possibility that
specific cancer antigens do not exist must be faced.
Instead of cancer-specific antigens, cancer-associated
antigens have been found. Some of these antigens are
considered time antigens. A cancer cell makes fetal
alkaline phosphatase, or a fetal pyruvate kinase
isozyme, or embryonic antigens, or structures such as
alpha-fetoproteins; place antigens also are made.
Thus a variety of normal hormones are made by
malignant cells derived from cells that have ceased
making these products. Frequently these hormones
produce symptoms in the patient, a paraneoplastic
syndrome. Were we to have the full catalog of normal
gene products made from conception to maturity, it
is possible that a time or place antigen or both could
be associated with every human cancer. The finding
of time and place cancer-associated antigens instead
of cancer-specific antigens fits in with an intriguing
new concept of the pathogenesis of cancer;• which as
its essential feature regards cancer as a programming
error. Carcinogenesis is not a mutation to new struc
tures but rather a reactivation of genetic programs
that were terminated a long time ago. In this view
viruses, chemicals, and physical agents act by going
· into the "old book" section of the cell's DNA library
and activating something long dormant.
It is possible to estimate the percent of the infor
mational DNA that is being actively transcribed by
cells. There is no difference in the amount of DNA
active in the blastula phase, the gastrula phase, or the
adult cells. About 3% of the DNA is being used, but
the 3% used in the gastrula phase cells is not identical
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to the 3% used by the blastula cells. Thus normal
development consists of the orderly and sequential
production and elimination of portions of the DNA
program.
Can programs be initiated? Dr. Ruddy referred
to androgen treatment of hereditary angioedema.
The administration of an androgen leads to synthesis
of a significant amount of a protein necessary to
inhibit spontaneous activation of the complement
system; other examples exist, perhaps the best being
the reactivation of the information locked up within a
cell nucleus as reported by Gurdon. 2' Trans
plantation of organelles produced striking results
when the nucleus of a fertilized frog ovum was re
moved and replaced by the nucleus of a mature frog
muscle cell. The microsurgically treated cell was then
restored to its proper environment, and development
of the ovum resulted in the formation of a tadpole.
All the information for this development was uncov
ered in an orderly fashion from the mature nucleus of
a differentiated cell. Similar results have been ob
tained when the nucleus from a mature frog lym
phocyte was transplanted into an enucleated ferti
lized frog ovum.
Our society seems to have more difficulty in for
mulating the correct questions than it does in provid
ing the answers to these questions. The finding of
several cancer-associated antigens emphasizes that
cancer immunologists must continue to examine
serologically the early stages of development with the
objective of identifying additional tumor-associated
antigens that in turn may be critical in establishing
valid early diagnostic tests for cancer.
The Nature of the Immune Defect in Cancer.
The failure to demonstrate an effective immuno
therapeutic method requires that the defects in the
immune surveillance and rejection system be exam
ined again with respect to cancer.
Does the patient who develops a carcinoma of
the lung, or breast, or stomach or other organs have a
defect that is applicable to the recognition and reac
tion to many antigens or is the defect confined to the
antigen or antigens associated with that particular
cancer? This is not a trivial question since the direc
tion for future immunotherapy depends on the an
swer. Arguments in favor of a broad defect are the
high incidence of neoplasm in transplant patients and
in those with immune deficiency diseases, but the
interpretation of this evidence is not decisive. Cy
totoxic immunotherapy is not exclusively immuno
suppressive. It may interfere with DNA repair mech-
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anisms which if unchecked could cause malignancy as
seen in xeroderma pigmentosa. 26 These patients have
a very high incidence of neoplasms of the skin, and
severe impairment of the ability to repair the damage
in DNA caused by ultraviolet irradiation. Many of
the drugs used in immunosuppression may also inter
fere with DNA repair mechanisms.
The evidence suggesting that there is no broad
immune defect in cancer patients is drawn from the
incidence of infection in patients with solid neo
plasms. Since the earliest days of immunology, in
fection has pointed to the areas where immune de
fects exist, and it is unusual to see clinically
significant immune defects without concomitant fre
quent infection. Indeed the defects may be so subtle,
as in sickle cell disease, that increased susceptibility
to infection is recognized long before the nature of
the immune defect is discovered.
Contrary to general opinion, infection is not a
common problem in the patient with solid cancers,
although infection certainly occurs when large masses
obstruct a passageway or become necrotic. If exten
sive chemotherapy renders the patient gran
ulocytopenic, or if large doses of steroids are given,
infection occurs, but under other circumstances, in
fection in a non-terminal cancer patient is rare. Ac
counts of infection in cancer patients are pre
dominantly those of patients with leukemia,
lymphoma, and myelorna. Of 93 patients with asper
gillosis, only 14 had solid tumors." Of these, 11 were
receiving steroids and nine were receiving cytotoxic
drugs. Another recent report'" shows that 31 of 35
patients treated for infection with sulfamethoxazole
trimethoprirn had hematologic malignancies; so it
goes with all reports of infection in cancer patients.
It appears to me unlikely that the overwhelming
majority of patients with solid tumors have a large
blind spot in their immune system. Skin testing for
anergy, counting T and B lymphocytes, and stimu
lating lymphocytes with mitogens can probably be
safely discontinued or replaced by looking for the
real defect in the immune system in cancer patients.
This leads to the second question. How does an
antigenic cancer escape detection') The answer to this
question is beset with technical difficulties. The re
ports of two workshops 29· designed to evaluate the
results of in vitro cytotoxicity tests for cancer cells are
gloomy. More emphasis needs to be placed upon
technical improvements in the culturing of cancer
cells and in determining their in vitro susceptibility to
antibody and to lymphocytes and macrophages.
30

Our understanding of this area is intimately tied
to our efforts in human cancer immunotherapy. An
outline of how a cancer breaks through or may break
through is of value even though it is purely specula
tive. Early studies in malignant melanoma" stressed
the importance of humoral antibodies. Patients with
localized melanoma were reported to have antibody
which reacted with melanoma cells while patients
with disseminated melanoma generally lacked these
antibodies. Using in vitro techniques, the Hellstroms
demonstrated a more complex Trojan Horse type of
immunologic arrangement" in which lymphocytes
from a cancer patient could destroy in vitro cancer
cells removed from that patient. This cellular immune
reaction could be inhibited by antibody present in the
serum of that cancer patient and from these observa
tions a dual immune system was formulated-an
tibody could protect the cancer, and cellular immun
ity could destroy the cancer. Further modifications
have been made in both the serum and cellular as
pects, but the basic premise remains that the destruc
tion or growth of a cancer depends upon the relative
strengths of two types of immune reactions. This
point should be returned to in considering the results
of immunotherapy.
Immunology and Early Diagnosis of Cancer.
Early diagnosis implies identification of the pres
ence and location of malignant cells at a time when
curative treatment can be performed. Today none of
the immunologic tests for cancer-associated antigens
are sensitive and specific enough to meet this require
ment.
The nature of the immunologic tests for cancer
associated antigens is qualitatively different from
tests measuring levels of liver enzymes or bone en
zymes. In the latter tests, it is unlikely that a small
mass could raise the level of normally present en
zymes to an abnormal level; that is, there is a high
background of normal activity that obscures the sim
ilar activity of the neoplastic cells. In the immuno
logic tests, the search is for fetal antigens in which the
background levels should be low. This is an area in
which future progress may produce valuable results.
f 111111unologic Treatment Monitoring A ids.
Three radioimmunoassay tests are currently of
great value in the management of patients with cancer.
The carcinoembryonic antigen (CEA) test is of
great assistance in management of some patients with
colorectal carcinoma. Where the level is elevated pre
operatively, the postoperative levels are useful in as-
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sessing the recurrence of disease and the response to
therapy. We are not recommending adjuvant post
operative chemotherapy, but an elevation in the CEA
is one indication to search for the location of the
recurrence and for initiation of therapy.
Radioimmunoassay of chorionic gonadotropins
has long been known to be essential in planning the
treatment of choriocarcinoma. The radio
immunoassays for alpha-fetoprotein and for the B
subunit of chorionic gonadotropin add a major new
dimension to our management of patients with testic
ular cancer. Decisions about starting chemotherapy
and the selection of the chemotherapy drugs used are
greatly influenced by the results of these immunologic
tests.
lmmunotherapy of Cancer.
I have not allotted much space to the analysis of
cancer immunotherapy. Many techniques-some
simple, some complex, and some very ingenious-are
being used to either treat human cancer or to prevent
its recurrence.
The experimental studies of BCG immunization
in the guinea pig" illustrate the potential value and
the limitations of immunotherapy. In this system,
injection of living Mycobacterium bovis BCG into the
tumor residing in an animal capable of developing
cellular reactivity to BCG, and at a time when the
tumor is small, results in a marked decrease in the
number of tumor-transplantation takes. Many exper
imental animal systems carefully designed to demon
strate an effect of immunotherapy have been pub
lished. The literature on human cancer
immunotherapy trials is enormous; its abundance
makes it difficult to discount. In my view the effec
tiveness of any immunotherapeutic procedure in hu
man cancer has yet to be demonstrated. There is great
interest in studying the results reported at the confer
ence "lmmunotherapy of Cancer: Present Status of
Trials in Man."
Predicting the future course of immunothera
pists is hazardous. The mood or moving spirit seems
to indicate a great disenchantment with BCG and its
allied products. A shift to Corynebacterium parvu/um
is underway, but it is probably too toxic to gain wide
acceptance. The newest bacterial entry is the pseudo
monas vaccine. The direction seems to be to go
through Bergey's Manual, a task that could involve
generations.
Ironically BCG is being rejected as uncritically
as it was accepted. If we are to be able to interpret an
immunotherapy trial properly, we need to know

more than the change in size of a cancer mass or the
duration of survival. We need measurements of the
changes in the levels of antitumor blocking antibody,
unblocking antibody, and cellular cytotoxicity and
cellular suppression. With this information we can
learn how to stimulate selectively the portion of the
immune response that destroys cancer without stimu
lating the immune response that aids cancer.
Conclusions.
Immunology provides a valuable tool as a treat
ment monitoring aid in many cancers.
The likelihood of an effective cancer vaccine is
remote and requires identification of both an onco
genic virus and a susceptible subgroup.
The failure to find cancer antigens and the abun
dance of cancer-associated antigens suggest that can
cer may be a programming error and potentially re
versible.
Immunology is likely to provide better and effec
tive early diagnostic tests.
The major need in immunotherapy is laboratory
support to measure the effects of therapy upon anti
tumor immune response.
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